Utilizing this resource-limitation-adapted PS imaging protocols, centres, across the developing world, may be able to leap-frog near the frontiers of modern PCa diagnostics with PSMA radioligand imaging (and potentially PSMA therapy and dosimetry), by “starting where they are, using what they have, and doing what they can” [65]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.